Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seqirus QIV vs Comparator QIV in Pediatric Population (5-17 Years)
NCT02545543Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Sep 2015
- Primary completion
- Jan 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of influenza B virus B/Brisbane/46/2015 antigen (propiolactone inactivated) in influenza, sponsored by CSL Seqirus. Started Sep 2015; status: completed.
02
Drugs
influenza B virus B/Brisbane/46/2015 antigen (propiolactone inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02545543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02545543.